Reckitt Benckiser, Bristol-Myers sales and marketing update

Reckitt Benckiser will acquire exclusive commercialization and distribution rights to OTC products from Bristol-Myers sold primarily in Mexico and Brazil. Bristol-Myers will receive an upfront payment of $438 million. The pharma will also be eligible for undisclosed royalties. Reckitt Benckiser will pay an additional $44 million for the option to acquire the products outright at the end of the three-year deal. If Reckitt Benckiser exercises the option, the purchase price would be based on average net sales during the two years preceding closing. ...